Company intelligence / Profile preview

Energenx

Ownership: Public · AIPG
Development stage: Phase 1

Overview

Energenx Medical has entered into an exclusive license agreement with Galvanize Therapeutics to develop and commercialize pulsed electric field therapies for COPD in Mainland China, Hong Kong, Taiwan, and Macau. The partnership aims to address significant unmet needs in these regions. No published clinical results are available as of June 2025.

Therapeutic areas: Pulmonology
Modalities: Device
Industry: Therapeutic Medical Devices

Drug pipeline

2 assets

RheOx

Phase 1

Indications: Chronic bronchitis, COPD

1 more asset in the full pipeline.

Request access →

Partnerships

Galvanize Therapeutics

Financials

Market cap: $4M
Total revenue: $0
Enterprise value: $4M

Beyond the preview

Go deeper on Energenx.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Energenx.

Explore the full profile